D E Casey

Summary

Country: USA

Publications

  1. ncbi request reprint Implications of the CATIE trial on treatment: extrapyramidal symptoms
    Daniel E Casey
    Department of Psychiatry, Oregon Health and Science University, Portland, OR 97239, USA
    CNS Spectr 11:25-31. 2006
  2. ncbi request reprint Atypical antipsychotics: enhancing healthy outcomes
    Daniel E Casey
    Mental Illness Research, Education and Clinical Center, MIRECC VISN 20, Portland VA Medical Center and the Department of Psychiatry, Oregon Health Sciences University, Portland, OR 97201, USA
    Arch Psychiatr Nurs 16:S12-9. 2002
  3. ncbi request reprint Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study
    Daniel E Casey
    Mental Health Division P3MIRECC, VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA
    Psychopharmacology (Berl) 166:391-9. 2003
  4. ncbi request reprint Metabolic issues and cardiovascular disease in patients with psychiatric disorders
    Daniel E Casey
    UHN 80 Department of Psychiatry, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA
    Am J Med 118:15S-22S. 2005
  5. ncbi request reprint Tardive dyskinesia and atypical antipsychotic drugs
    D E Casey
    Mental Health Division, Veterans Affairs Medical Center, Portland, OR 97207, USA
    Schizophr Res 35:S61-6. 1999
  6. ncbi request reprint Tardive dyskinesia: pathophysiology and animal models
    D E Casey
    Mental Illness Research, Education and Clinical Center, Veterans Affairs Medical Center, Portland, OR 97201, USA
    J Clin Psychiatry 61:5-9. 2000
  7. ncbi request reprint Barriers to progress--the impact of tolerability problems
    D E Casey
    Psychiatric Research and Psychopharmacology, Mental Health Division, Veterans Affairs Medical Center, Portland, Oregon, USA
    Int Clin Psychopharmacol 16:S15-9. 2001
  8. ncbi request reprint Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia
    Daniel E Casey
    Mental Illness Research, Education, and Clinical Center, Portland VA Medical Center, OR 97201, USA
    Neuropsychopharmacology 28:182-92. 2003
  9. ncbi request reprint The pharmacology of weight gain with antipsychotics
    D E Casey
    Portland Veterans Affairs Medical Center, Oregon Health Sciences University, USA
    J Clin Psychiatry 62:4-10. 2001
  10. ncbi request reprint Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys
    J Gerlach
    Dept of Psychiatry, Veterans Administration Medical Center, Portland, Oregon
    Prog Neuropsychopharmacol Biol Psychiatry 14:103-12. 1990

Detail Information

Publications23

  1. ncbi request reprint Implications of the CATIE trial on treatment: extrapyramidal symptoms
    Daniel E Casey
    Department of Psychiatry, Oregon Health and Science University, Portland, OR 97239, USA
    CNS Spectr 11:25-31. 2006
    ..This article explores the reported results of the CATIE trial regarding EPS and emphasizes the differentiation of the atypicals from perphenazine on EPS and how these results should be incorporated into daily practice for the clinician...
  2. ncbi request reprint Atypical antipsychotics: enhancing healthy outcomes
    Daniel E Casey
    Mental Illness Research, Education and Clinical Center, MIRECC VISN 20, Portland VA Medical Center and the Department of Psychiatry, Oregon Health Sciences University, Portland, OR 97201, USA
    Arch Psychiatr Nurs 16:S12-9. 2002
  3. ncbi request reprint Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study
    Daniel E Casey
    Mental Health Division P3MIRECC, VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA
    Psychopharmacology (Berl) 166:391-9. 2003
    ..It is important to compare switching strategies to determine which methods produce the best possible patient outcomes...
  4. ncbi request reprint Metabolic issues and cardiovascular disease in patients with psychiatric disorders
    Daniel E Casey
    UHN 80 Department of Psychiatry, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA
    Am J Med 118:15S-22S. 2005
    ..The costs associated with the treatment of the metabolic syndrome, diabetes, and coronary heart disease in populations with schizophrenia are also described...
  5. ncbi request reprint Tardive dyskinesia and atypical antipsychotic drugs
    D E Casey
    Mental Health Division, Veterans Affairs Medical Center, Portland, OR 97207, USA
    Schizophr Res 35:S61-6. 1999
    ..Because TD liability is so much lower with novel antipsychotic therapy, all patients who have TD or are at risk for TD, as well as EPS, should be considered candidates for switching to these new drugs...
  6. ncbi request reprint Tardive dyskinesia: pathophysiology and animal models
    D E Casey
    Mental Illness Research, Education and Clinical Center, Veterans Affairs Medical Center, Portland, OR 97201, USA
    J Clin Psychiatry 61:5-9. 2000
    ..Fortunately, the atypical antipsychotic agents appear to greatly decrease the liability of developing tardive dyskinesia, but how this occurs remains an open and fascinating line of inquiry...
  7. ncbi request reprint Barriers to progress--the impact of tolerability problems
    D E Casey
    Psychiatric Research and Psychopharmacology, Mental Health Division, Veterans Affairs Medical Center, Portland, Oregon, USA
    Int Clin Psychopharmacol 16:S15-9. 2001
    ..The more favourable the benefit/risk ratios of these new drugs throughout all phases of treatment, the greater the likelihood that patients will have better outcomes...
  8. ncbi request reprint Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia
    Daniel E Casey
    Mental Illness Research, Education, and Clinical Center, Portland VA Medical Center, OR 97201, USA
    Neuropsychopharmacology 28:182-92. 2003
    ..Further evaluation is warranted to confirm these findings...
  9. ncbi request reprint The pharmacology of weight gain with antipsychotics
    D E Casey
    Portland Veterans Affairs Medical Center, Oregon Health Sciences University, USA
    J Clin Psychiatry 62:4-10. 2001
    ..In spite of this, an overview of current knowledge in the field may facilitate prediction of a potential novel antipsychotic agent's weight gain liability...
  10. ncbi request reprint Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys
    J Gerlach
    Dept of Psychiatry, Veterans Administration Medical Center, Portland, Oregon
    Prog Neuropsychopharmacol Biol Psychiatry 14:103-12. 1990
    ....
  11. ncbi request reprint The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates
    D E Casey
    Mental Health Division (P-3-MHDC, VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, OR 97207, USA
    Psychopharmacology (Berl) 157:228-35. 2001
    ....
  12. ncbi request reprint Clinical trial design issues in schizophrenic research
    D E Casey
    Mental Illness Research, Education and Clinical Center, Veterans Administration Medical Center, and the Oregon Health Sciences University, Portland 97201, USA
    J Clin Psychiatry 62:17-20; discussion 21-2. 2001
    ..This article discusses the 2 major goals of research studies, the design issues associated with those goals, and the design features of several recent comparative studies of atypical antipsychotics...
  13. ncbi request reprint Dyslipidemia and atypical antipsychotic drugs
    Daniel E Casey
    Department of Psychiatry, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    J Clin Psychiatry 65:27-35. 2004
    ....
  14. ncbi request reprint Metabolic effects of treatment with atypical antipsychotics
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA
    J Clin Psychiatry 65:1447-55. 2004
  15. ncbi request reprint Physical health monitoring of patients with schizophrenia
    Stephen R Marder
    Department of Veterans Affairs Greater Los Angeles Healthcare System, CA, USA
    Am J Psychiatry 161:1334-49. 2004
    ..The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings...
  16. ncbi request reprint Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia
    Daniel E Casey
    J Clin Psychiatry 65:4-18; quiz 19-20. 2004
  17. ncbi request reprint Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Psychiatr Serv 55:290-4. 2004
    ....
  18. ncbi request reprint Long-term treatment goals: enhancing healthy outcomes
    Daniel E Casey
    Oregon Health and Science University, Portland, Oregon, USA
    CNS Spectr 8:26-8. 2003
    ..These drugs are likely to provide physicians with an increasingly viable option in the long-term treatment and rehabilitation of patients with schizophrenia...
  19. ncbi request reprint Effect of a novel potential atypical antipsychotic drug, Y-931, in producing dystonia in cebus monkeys
    Yasuyuki Shiigi
    Research Laboratory I CNS, Pharmaceuticals Research Unit, Research and Development Division, Mitsubishi Pharma Corporation, Iruma, Saitama, Japan
    J Pharmacol Sci 93:364-6. 2003
    ..5 mg/kg, i.m., the scores did not exceed 20, up to a dose of 1.0 mg/kg, i.m. and lacked a dose-response relationship. The present result suggests that Y-931 is predicted to have a low risk of extrapyramidal side effects...
  20. ncbi request reprint Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo
    Gilbert J L'italien
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
    J Clin Psychiatry 68:1510-6. 2007
    ....
  21. ncbi request reprint Pathophysiology of antipsychotic drug-induced movement disorders
    Daniel E Casey
    Department of Psychiatry and Neurology, Oregon Health and Sciences University, Portland, OR 97321, USA
    J Clin Psychiatry 65:25-8. 2004
    ..A number of factors contribute to the difficult task of gaining insight into the pathophysiologic processes of antipsychotic agents and why these agents may lead to drug-induced movement disorders...
  22. ncbi request reprint Schizophrenia and increased risks of cardiovascular disease
    Charles H Hennekens
    Department of Biomedical Science, Center of Excellence in Biomedical and Marine Biotechnology, Florida Atlantic University, FL, USA
    Am Heart J 150:1115-21. 2005
    ..The aim of the study is to review the absolute and relative impacts of the major causes for premature mortality among patients with schizophrenia...
  23. ncbi request reprint Response to letter to the editor by Dr Mackin
    Charles H Hennekens
    Am Heart J 152:e59. 2006